To include your compound in the COVID-19 Resource Center, submit it here.

Making a better PDE-4 inhibitor

Choking on Ariflo

Making a better PDE-4 inhibitor

The rationale for targeting phosphodiesterase-4 (PDE-4) in chronic obstructive pulmonary disorder (COPD) is straightforward: it reduces inflammatory cell activity. But companies have had limited success in developing inhibitors of the enzyme, as underlined by last week's failure of Ariflo cilomilast from GlaxoSmithKline plc to win the endorsement of an

Read the full 552 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers